Please login to the form below

Not currently logged in
Email:
Password:

Larry Bell joins Dutch biopharma Prosensa

Takes up role as head of global regulatory affairs

Prosena Larry BellDutch biopharmaceutical company Prosensa Therapeutics has appointed Larry Bell as head of global regulatory affairs.

He joins the Leiden-based company with more than 18 years of regulatory affairs experience gained at companies that include Merck, Bristol-Myers Squibb, Aventis and Amgen.

Prior to setting up his own consultancy, his most recent role was as vice president and global head of regulatory affairs at GE Healthcare

For his new role at Prosensa, which focuses on RNA-modulating therapeutics for rare diseases with high unmet need, Bell will be based in the US and oversee the company's global regulatory activities.

Bell said: “This is a key time to be joining the Prosensa team. As the orphan drugs space grows in size and scope, there are many regulatory considerations that need to be addressed in order for new drugs to reach the patients that need them.

“I look forward to helping progress Prosensa's cutting-edge therapies through the regulatory process.”

18th February 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...